Business Context and Reporting Period
Company: OS Therapies Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2026 (Event Date)
Closing Date: April 2, 2026
Context: The Company, an emerging growth company, announced the entry into a Material Definitive Agreement for a registered direct offering of equity securities.
Key Financial Metrics and Transaction Details
Transaction Overview: Registered Direct Offering of common stock, pre-funded warrants, and common warrants.
Net Proceeds: Approximately $4.7 million.
Use of Proceeds: Funding clinical development activities, advancing R&D programs, potential acquisitions/investments, and working capital.
| Security Type | Quantity | Purchase Price |
|---|---|---|
| Common Stock | 2,505,073 shares | $1.40 per share (combined with warrant) |
| Pre-Funded Warrants | 1,250,893 shares | $1.399 per warrant (combined with warrant) |
| Common Warrants | 3,755,966 shares | Issued alongside stock/pre-funded warrants |
Placement Agent Fees:
- Cash Fee: 7.0% of gross proceeds.
- Expense Reimbursement: Up to $70,000 (accountable) and $20,000 (non-accountable).
- Placement Agent Warrants: 187,798 shares (5.0% of aggregate offering), exercise price $1.54.
Material Changes and Covenants
The filing does not provide comparative financial metrics (revenue, profit, cash flow) as this is a transactional 8-K rather than a periodic financial report. Material changes relate to capital structure and liquidity:
- Liquidity Increase: Immediate infusion of approximately $4.7 million in net proceeds.
- Dilution: Issuance of significant new equity and warrant instruments.
- Issuance Restrictions (Lock-up):
- 90-day blackout period on issuing new common stock or convertible securities (with exceptions).
- 180-day restriction on Variable Rate Transactions.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize proceeds to fund ongoing and planned clinical trials and advance research and development programs. The offering was executed to support strategic objectives and general corporate purposes.
Risks and Contingencies:
- Forward-Looking Statements: The filing contains forward-looking statements regarding the use of proceeds, which are subject to risks and uncertainties including financial position and market conditions.
- Warrant Terms: Common warrants expire five years from issuance. Pre-funded warrants expire only when fully exercised. Neither warrant type will be listed on a public exchange.
- Ownership Caps: Warrant holders are restricted from exercising if it causes beneficial ownership to exceed 4.99% (or 9.99% at election) without prior notice.
Investor Verification Checklist
- Verify the final closing date and exact net proceeds received (stated as approx. $4.7 million).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination provisions and representations.
- Confirm the impact of the 7.0% placement fee and warrant issuance on total shareholder dilution.
- Monitor the Company's cash burn rate relative to the $4.7 million raised to assess runway for clinical trials.
- Check subsequent filings for any updates on the status of the clinical development activities funded by this offering.